en
jalali
1396
6
1
gregorian
2017
9
1
21
5
online
1
fulltext
en
Precision Medicine: A New Revolution in Healthcare System
Every human being is different based on genetics, lifestyle, and environmental factors. Novel medical technologies have become more precise owing to molecular information, including genomics, transcriptomics, proteomics, metabolomics, etc. The “omics” technologies have opened up new horizons for healthcare systems, enabling them to prevent and/or diagnose diseases more precisely, as well as to find the most effective treatments with fewer adverse events. Recently, the term ‘precision medicine’ (PM), focusing on molecular-based medicine, has been introduced. PM empowered by “omics” technologies is going to be translated into precision healthcare. In other words, personalized healthcare is developed to improve the safety and efficacy of medical treatments and also to lower healthcare costs. Accordingly, some PM initiatives have been announced in the US and European countries to revolutionize healthcare systems. In the field of drug discovery, there are concerns about the role of genomics and proteomics in individual response to medicines. Information coming from “omics” such as genomics, proteomics, metabolomics, epigenomics, transcriptomics, and antibodyomics based on molecular characteristics of patients will enable physicians to administer safer and more effective drugs to each individual...
282
283
http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-1-665&slc_lang=en&sid=1
2017/05/31
1396/3/10
2017/05/31
1396/3/10
Babak
Arjmand
Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran
00319475328460055463
00319475328460055463
Yes
Mohammad
Abdollahi
Toxicology and Diseases Group, Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran;
00319475328460055464
00319475328460055464
No
Bagher
Larijani
Virtual Center for Review of Medical Sciences, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran;
00319475328460055465
00319475328460055465
No
en
Misconduct in Research and Publication
Dear Editor, I read the recent publication on “Misconduct in Research and Publication” with great interest[1]. I agree that misconduct in research and publication is not uncommon. Nevertheless, it is rarely mentioned. In fact, there are many incorrect conceptions among researchers on publication ethics. The milder examples are attempts to report only the “positive outcomes”, textual or data recycling as well as figure cropping and modification. These problems can be seen in published work of many academic members regardless of nationality or seniority. To provide the needed education and instructions aiming at primary prevention of the problem is widely practiced. A secondary means of prevention is screening for misconduct for the purpose of early detection. Nevertheless, such misconduct is repeatedly observed.
An important question is whether such measures are suitable corrective actions. In general, if the misconduct is detected, reporting to the researchers’ organization, as well as retraction of the articles with public announcement by the journal, are recommended. Nevertheless, there is often no incurred penalty or response from the researchers under question or their affiliated organizations. If those committing the misconducts are senior academics, they might receive no penalty and may even be further promoted based those questionable publications[2]. Sometimes, the journals, which are usually of poor quality and predatory type also support the misconduct incidence[2]. Such behavior sets fallacious examples for the rest. Of interest, although there are extensive attempts to promote anti-misconduct communities, which normally fail. A good example is the launching of Déjà vu database to combat plagiarism[3], which is currently non-functional. How to promote the ethical practice among the practitioners and promote the anti-misconduct community is a major challenge facing our scientific community.
Misconduct, Publication, Research
284
284
http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-1-663&slc_lang=en&sid=1
2017/05/312017/05/29
1396/3/8
2017/05/312017/05/29
1396/3/8
Viroj
Wiwanitkit
Visiiting Professor, Hainan Medical University, China; Honorary Professor, Dr. DY Patil University, China
00319475328460055466
00319475328460055466
Yes
en
Therapeutic effects of Iranian herbal extracts
against Trichomonas vaginalis
Trichomonas vaginalis is a flagellated parasite affecting about 276 million people annually worldwide. Tricomoniasis is associated with different complications in pregnant women and infants. 5'-nitroimidazole derivatives (metronidazole, ornidazole, and tinidazole) are FDA approved drugs recommended for trichomoniasis treatment. Treatment with metronidazole 5'-nitroimidazole derivatives is associated with many side effects, and drug resistance to metronidazole has been reported in some cases. Recently, many attempts have been made to evaluate the effects of plants on causative agents of vaginal infections. In our research, the national and international databases were searched and the effects of various herbal extracts on T. vaginalis in Iran were reviewed from 2006 to 2016. In articles investigated, some plants had favorable antitrichomonal effects and needed to be further investigated. All the plant extracts have only been evaluated in vitro. Surveys of different articles in this review show that the active ingredients present in different parts of plants, including aerial parts, leaves, flowers, stems, and root can be suitable sources for introducing and developing new antitrichomonal compounds.
Trichomonas vaginalis, Medicinal plants, Iran, Herbal, Extract
285
293
http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-1-682&slc_lang=en&sid=1
2017/05/312017/05/292017/07/25
1396/5/3
2017/05/312017/05/292017/07/25
1396/5/3
Zohreh
Fakhrieh Kashan
Department of Medical Parasitology, School of Public Health , Tehran University of Medical Sciences, Tehran, Iran
00319475328460055467
00319475328460055467
No
Mahdi
Delavari
Department of Medical Parasitology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
00319475328460055468
00319475328460055468
Yes
Mohsen
Arbabi
Department of Medical Parasitology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
00319475328460055469
00319475328460055469
No
Hossein
Hooshyar
Department of Medical Parasitology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
00319475328460055470
00319475328460055470
No
en
Homozygosity Mapping and Targeted Sanger Sequencing Identifies Three Novel CRB1 (Cumbs homologue 1) Mutations in Iranian Retinal Degeneration Families
Background: Inherited retinal diseases (IRDs) are a group of genetic disorders with high degrees of clinical, genetic and allelic heterogeneity. IRDs generally show progressive retinal cell death resulting in gradual vision loss. IRDs constitute a broad spectrum of disorders including retinitis pigmentosa and Leber congenital amaurosis. In this study, we performed genotyping studies to identify the underlying mutations in three Iranian families. Methods: Having employed homozygosity mapping and Sanger sequencing, we identified the underlying mutations in the crumbs homologue 1 gene. The CRB1 protein is a part of a macromolecular complex with a vital role in retinal cell polarity, morphogenesis, and maintenance. Results: We identified a novel homozygous variant (c.1053_1061del; p.Gly352_Cys354del) in one family, a combination of a novel (c.2086T>C; p.Cys696Arg) and a known variant (c.2234C>T, p.Thr745Met) in another family and a homozygous novel variant (c.3090T>A; p.Asn1030Lys) in a third family. Conclusion: This study shows that mutations in CRB1 are relatively common in Iranian non-syndromic IRD patients.
Retinal degeneration, Retinitis pigmentosa, Leber congenital amaurosis, Mutation, Iran
294
302
http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-2438-3&slc_lang=en&sid=1
2017/05/312017/05/292017/07/252017/05/2
1396/2/12
2017/05/312017/05/292017/07/252017/05/2
1396/2/12
Mohammad
Ghofrani
Department of Medical Genetics, Tehran University of Medical Sciences, Tehran, Iran.
00319475328460055471
00319475328460055471
Yes
Mahin
Yahyaei
Department of Medical Genetics, Tehran University of Medical Sciences, Tehran, Iran.
00319475328460055472
00319475328460055472
No
Han G.
Brunner
Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
00319475328460055473
00319475328460055473
No
Frans P.M.
Cremers
Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
00319475328460055474
00319475328460055474
No
Morteza
Movasat
Eye Research Center, Tehran University of Medical Sciences, Farabi Eye Hospital, Tehran, Iran
00319475328460055475
00319475328460055475
No
Muhammad
Imran Khan
Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands
00319475328460055476
00319475328460055476
No
Mohammad
Keramatipour
Department of Medical Genetics, Tehran University of Medical Sciences, Tehran, Iran
00319475328460055477
00319475328460055477
No
en
Expression Study and Clinical Correlations of MYC
and CCAT2 in Breast Cancer Patients
Background: Colon cancer-associated transcript 2 (CCAT2) is a newly recognized lncRNA transcribed from the 8q24 genomic region. It functions as an oncogene in various types of cancers including breast cancer, in which it affects Wnt/β-catenin pathway. Previous studies have shown a putative interaction between this lncRNA and MYC proto-oncogene. Methods: In the current study, we evaluated the expression of CCAT2 in breast cancer tissues with regards to the expression of its target MYC. In addition, we assessed the relationship between CCAT2 and MYC expression levels in tumor tissues and the clinical prognostic characteristics of breast cancer patients. Results: MYC expression levels were significantly up-regulated in tumor tissues compared with adjacent non-cancerous tissues (ANCTs), while such analysis showed no statistically significant difference between these two tissue types in CCAT2 expression. Starkly increased CCAT2 gene expression levels were found in 12/48 (25%) of cancer tissue samples compared with their corresponding ANCTs. Furthermore, significant inverse correlations were found between CCAT2 expression and stage, as well as lymph node involvement. Besides, a significant inverse correlation was found between the relative MYC expression in tumor tissues compared with their corresponding ANCTs and disease stage. Conclusions: These results highlight the significance of MYC and CCAT2 expressions in the early stages of breast cancer development and suggest a potentially significant role for CCAT2 in a subset of breast cancer patients, which could applied as a potential therapeutic target in these patients.
Long non-coding RNA, Breast cancer, c-MYC
303
311
http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-1-659&slc_lang=en&sid=1
2017/05/312017/05/292017/07/252017/05/22017/05/8
1396/2/18
2017/05/312017/05/292017/07/252017/05/22017/05/8
1396/2/18
Shaghayegh
Sarrafzadeh
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
00319475328460055478
00319475328460055478
No
Lobat
Geranpayeh
Department of Surgery, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
00319475328460055479
00319475328460055479
No
Behnoosh
Tasharrofi
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
00319475328460055480
00319475328460055480
No
Mohammad
Soudyab
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
00319475328460055481
00319475328460055481
No
Elahe
Nikpayam
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
00319475328460055482
00319475328460055482
No
Mostafa
Iranpour
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
00319475328460055483
00319475328460055483
No
Reza
Mirfakhraie
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
00319475328460055484
00319475328460055484
No
Jalal
Gharesouran
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
00319475328460055485
00319475328460055485
No
Somayyeh
Ghafouri-Fard
Department of Community and Preventive Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
00319475328460055486
00319475328460055486
No
Soudeh
Ghafouri-Fard
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
00319475328460055487
00319475328460055487
Yes
en
Accuracy of Soluble Endoglin for Diagnosis of Preeclampsia and its Severity
Background: The use of biomarkers for diagnosis of Preeclampsia (PE), a life-threatening pregnancy disorder, could reduce serious complications of this disease. In this study, we investigated dysregulation of endoglin (Eng) expression and diagnostic accuracy of soluble endoglin (sEng) in PE patients. Methods: For this case-control study, 26 mild and 15 severe preeclamptic women along with 20 normotensive controls were recruited. The expression level of Eng (the co-receptor TGF-β1) was evaluated using qRT-PCR. Also, the serum concentration of soluble Eng and expression of membranous Eng were determined by ELISA and immunohistochemistry. Results: A significant up-regulation in Eng mRNA and sEng levels was observed in PE patients versus normal controls. Immunohistochemistry (IHC) showed up-regulation of membranous Eng staining in syncytiotrophoblast and cytotrophoblast cells of PE patients. The serum levels of sEng were significantly increased in all patients (mild, sever, early- and late-onset) as compared to healthy pregnant women (P˂0.001). Receiver-operating characteristic (ROC) curve analysis revealed that sEng had the highest accuracy in distinguishing PE from normal pregnancies with cut-off value of 20.4, sensitivity of 92.1%, specificity of 90%, and area under the curve (AUC) of 0.94 (95% CI: 0.88-1.00). Conclusions: Our data showed that the up-regulation of Eng mRNA along with its membranous and soluble form in PE patients leads to defect in angiogenesis pathway. Also, the results of this study revealed sEng potential as a marker for diagnosis of PE and its severity.
Preeclampsia, Endoglin, Biomarkers, Pregnancy
312
320
http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-1-666&slc_lang=en&sid=1
2017/05/312017/05/292017/07/252017/05/22017/05/82017/05/31
1396/3/10
2017/05/312017/05/292017/07/252017/05/22017/05/82017/05/31
1396/3/10
Pooneh
Nikuei
Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran;
00319475328460055488
00319475328460055488
Yes
Minoo
Rajaei
Fertility and Infertility Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran;
00319475328460055489
00319475328460055489
No
Kianoosh
Malekzadeh
Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
00319475328460055490
00319475328460055490
No
Azim
Nejatizadeh
Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
00319475328460055491
00319475328460055491
No
Fatemeh
Mohseni
Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
00319475328460055492
00319475328460055492
No
Ali
AtashAbParvar
Pathology Department, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
00319475328460055493
00319475328460055493
No
en
Serum Antibodies against Helicobacter pylori Neutrophil Activating Protein in Carriers of IL-4 C-590T Genetic Polymorphism Amplify the Risk of Gastritis and Gastric Cancer
Serum Antibodies against Helicobacter pylori Neutrophil Activating Protein in Carriers of IL-4 C-590T Genetic Polymorphism Amplify the Risk of Gastritis and Gastric Cancer
Background: Gastric cancer arises, mainly, on an inflammatory background. Helicobacter pylori neutrophil activating (HP-NAP) protein functions as a potent pro-inflammatory mediator. Similarly, IL-4 plays a critical role in the inflammation pathway, the levels of which are altered by C to T transition at position -590 in its promoter region. Here, we have aimed to assess the risk of gastritis and gastric cancer in the co-presence of these two inflammation modulating mediators. Methods: Gastritis (n=58) and gastric cancer (n=31) patients were evaluated and compared with H. pylori-positive asymptomatic controls (n=46), for serum antibodies against recombinant HP-NAP and IL-4 C-590T single nucleotide polymorphism using immunoblotting and PCR-RFLP, respectively. Multivariable logistic regression, adjusting for age, gender and ethnicity, was used for data analysis. Results: In terms of susceptibility to gastritis, seropositivity to HP-NAP projected a risk impact of 4.62 fold (OR=4.62, 95% CI=1.50-14.22), which when present in IL-4 -590 T carriers augmented the risk up to 9.7 fold (OR=9.70, 95% CI=2.06-45.69). A similar pattern, but of a stronger magnitude, occurred for the risk of gastric cancer, which was estimated at 9.07 fold (OR=9.07, 95% CI=1.99-42.0) for HP-NAP-seropositive subjects and was drastically amplified (OR=33.64, 95% CI=2.06-548.68), when double-positive (HP-NAP seropositive/IL-4 -590 T carrier) subjects were examined against double negatives (HP-NAP seronegative/IL-4 -590 CC). Conclusion: Our preliminary data indicate that serum antibodies against HP-NAP represent a state of risk, which is further exacerbated in IL-4 -590 T carriers. These biomarkers, if validated in larger prospective studies, can be used to screen for gastric cancer susceptibility.
Biomarkers, Genetic Polymorphism, Recombinant
321
329
http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-1-641&slc_lang=en&sid=1
2017/05/312017/05/292017/07/252017/05/22017/05/82017/05/312016/12/20
1395/9/30
2017/05/312017/05/292017/07/252017/05/22017/05/82017/05/312016/12/20
1395/9/30
Yeganeh
Talebkhan
HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
00319475328460055494
00319475328460055494
No
Mohsen
Doozbakhshan
HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
00319475328460055495
00319475328460055495
No
Samaneh
Saberi
HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
00319475328460055496
00319475328460055496
No
Maryam
Esmaeili
HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
00319475328460055497
00319475328460055497
No
Najmeh
Karami
HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
00319475328460055498
00319475328460055498
No
Nazanin
Mohajerani
HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
00319475328460055499
00319475328460055499
No
Afshin
Abdirad
Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
00319475328460055500
00319475328460055500
No
Mahmoud
Eshagh Hosseini
Department of Gastroenterology, Amiralam Hospital, Tehran University of Medical Sciences, Tehran, Iran
00319475328460055501
00319475328460055501
No
Azin
Nahvijou
Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran
00319475328460055502
00319475328460055502
No
Mohammad Ali
Mohagheghi
Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran
00319475328460055503
00319475328460055503
No
Marjan
Mohammadi
HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
00319475328460055504
00319475328460055504
Yes
en
Synergistic Effects of Arsenic Trioxide and Radiation: Triggering the Intrinsic Pathway of Apoptosis
Background: Arsenic trioxide (ATO) has been reported as an effective anti-cancer and a US Food and Drug Administration (FDA) approved drug for treatment of some cancers. The aim of this study is to determine the underlying apoptosis molecular and cellular mechanisms of ATO in the presence or absence of ionizing radiation (IR) in vitro in the glioblastoma multiforme (GBM) cell line, U87MG. Methods: Cells were treated by different concentrations of ATO either in presence or absence of IR. Viability and apoptosis pathway of both treated and control groups were evaluated using MTT assay and the expression analysis of Bax, Bcl-2, and caspase-3 genes, respectively. All treatments were performed on 100-μm diameter spheroids. Results: Results showed a significant reduction in the survival of the cells in all treated groups. As expected, cell survival was much less in combination treatment than treatment with only ATO. Moreover, combination therapy made Bax and caspase-3 up-regulated and Bcl-2 down-regulated. Conclusion: ATO and radiation had a synergistic apoptotic effect on GBM cells by up-regulation of caspase-3 and alteration of the Bax-Bcl-2 balance; therefore, ATO may act as a potential anti-cancer agent against GBM cells through triggering the mitochondrial pathway of apoptosis.
Arsenic trioxide, Radiation, Apoptosis, Glioblastoma, Spheroids
330
337
http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-1-658&slc_lang=en&sid=1
2017/05/312017/05/292017/07/252017/05/22017/05/82017/05/312016/12/202017/05/1
1396/2/11
2017/05/312017/05/292017/07/252017/05/22017/05/82017/05/312016/12/202017/05/1
1396/2/11
Kave
Moloudi
Radiation Sciences Department, Faculty of allied Medicine school, Iran University of Medical Sciences, Tehran, Iran
00319475328460055505
00319475328460055505
Yes
Ali
Neshasteriz
Radiation biology research center, Iran University of medical sciences, Tehran, Iran
00319475328460055506
00319475328460055506
No
Arshad
Hosseini
Department of Medical Biotechnology, Faculty of allied Medicine, Iran University of Medical Sciences, Tehran, Iran
00319475328460055507
00319475328460055507
No
Nazila
Eyvazzadeh
Radiation Research Center, Faculty of Paramedicine, AJA University of Medical sciences, Tehran, Iran
00319475328460055508
00319475328460055508
No
Mehdi
Shomali
Radiology Department, Faculty of allied Medicine, Tehran University of Medical Sciences, Tehran, Iran
00319475328460055509
00319475328460055509
No
Samira
Eynali
Medical physics and Biomedical Engineering Department, school of Medicine, Tran University of Medical Sciences, Tehran, Iran
00319475328460055510
00319475328460055510
No
Elahe
Mirzaei
Microbiology Department, Faculty of Science, Islamic Azad University, Tehran, Iran
00319475328460055511
00319475328460055511
No
Asaad
Azarnezhad
Cellular & Molecular Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran
00319475328460055512
00319475328460055512
No
en
Next-Generation Sequencing Reveals One Novel Missense Mutation in COL1A2 Gene in an Iranian Family
with Osteogenesis imperfecta
Background: Osteogenesis imperfecta (OI) is a clinically and genetically heterogeneous disorder characterized by bone loss and bone fragility. The aim of this study was to investigate the variants of three genes involved in the pathogenesis of OI. Methods: Molecular genetic analyses were performed for COL1A1, COL1A2, and CRTAP genes in an Iranian family with OI. The DNA samples were analyzed by next-generation sequencing (NGS) gene panel and Sanger sequencing. Results: Five different variants were identified in COL1A1 and COL1A2, including two variants in COL1A1 and three variants in COL1A2. Among the five causative COL1A1 and COL1A2 variants, one novel variants, c.1081 G>A, was found in COL1A2, which was identified in two siblings. Conclusion: Our finding extends the variant spectrum of the COL1A2 gene and has important implications for genetic counseling of families. The NGS is a powerful molecular diagnostic strategy for OI, a heterogeneous disorder.
Collagen type I, COL1A2, Mutation, Osteogenesis imperfecta, Next-generation sequencing
338
341
http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-1-655&slc_lang=en&sid=1
2017/05/312017/05/292017/07/252017/05/22017/05/82017/05/312016/12/202017/05/12017/04/22
1396/2/2
2017/05/312017/05/292017/07/252017/05/22017/05/82017/05/312016/12/202017/05/12017/04/22
1396/2/2
Farah
Talebi
Department of Genetic, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran
00319475328460055513
00319475328460055513
No
Farideh
Ghanbari Mardasi
Department of Midwifery, Shoushtar Faculty of Medical Science, Shoushtar, Iran
00319475328460055514
00319475328460055514
Yes
Javad
Mohammadi Asl
Department of Medical Genetics, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
00319475328460055515
00319475328460055515
No
Amir Hooshang
Bavarsad
Department of Internal Medicine, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
00319475328460055516
00319475328460055516
No
Masoumeh
Salehi Kambo
Department of Midwifery, Shoushtar Faculty of Medical Sciences, Shoushtar, Iran
00319475328460055517
00319475328460055517
No
fa
Molecular Characterization and Biodiversity of a Putative Chlorotoxin from the Iranian Yellow Scorpion Odontobuthus doriae
Background: Chloride channels have already been over-expressed in the different types of cancer. Chlorotoxins, as the blocking agent of these channels, have been indicated to be an effective drug against tumors. In this study, we characterized a putative chlorotoxin from a cDNA library of the venom glands obtained from the Iranian scorpion Odontobuthus doriae. Methods: A cDNA library was constructed from venom gland transcriptome of six scorpions. The cDNA encoding Odontobuthus doriae chlorotoxin was isolated from the library, and its putative peptide was characterized by some bioinformatics software such as protein blast, SignalP4.0, DISULFIND and Clustal Omega. Results: The mature Odontobuthus doriae chlorotoxin peptide has a 35-amino-acid residue and four disulfide bounds. This putative chlorotoxin is a small, compact, and stable molecule. Moreover, based on the open reading frame sequence similarity, this peptide is similar to Buthus martensii Karsch chlorotoxin‑like toxin and Bm12-b neurotoxins from the Chinese scorpion Mesobuthus martensii. Conclusion: The small size of this putative chlorotoxin and its stability make it as a suitable candidate for medical and pharmacological research, especially in the cancer research.
Chlorotoxin, Scorpion, Odontobuthus doriae, cDNA library
342
346
http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-1-654&slc_lang=en&sid=1
2017/05/312017/05/292017/07/252017/05/22017/05/82017/05/312016/12/202017/05/12017/04/222017/04/18
1396/1/29
2017/05/312017/05/292017/07/252017/05/22017/05/82017/05/312016/12/202017/05/12017/04/222017/04/18
1396/1/29
Maryam
Naderi Soorki
Department of Genetics, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran
00319475328460055518
00319475328460055518
No
Amir
Jalali
Department of Pharmacology and Toxicology, School of Pharmacy and Toxicology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
00319475328460055519
00319475328460055519
No
Hamid
Galehdari
Department of Genetics, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran
00319475328460055520
00319475328460055520
Yes